Peter Wells-Jordan - Department of Pathology, Leicester Royal Infirmary, Infirmary Square, Leicester, Leicestershire, UK.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Gut Microbiota Rheostat Forecasts Responsiveness to PD-L1 and VEGF Blockade in Mesothelioma

NATURE COMMUNICATIONSno. 1 (2024)

引用0浏览0WOSNATURE引用

Abstract 666: ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants

Dean Anthony Fennell,Joanna Dzialo, Jan Rogel,Daniel Faulkner,Nada Nusrat,Aleksandra Bzura,Kudzayi Kutywayo,Peter Wells-Jordan,Charlotte Poile,Andrea Biondo,Martin Sims,Apostolos Nakas,Jin-Li Luo,Min Zhang,Maria Ahn

Cancer Researchno. 6_Supplement (2024): 666-666

引用0浏览0引用

208 SynthEtic LEthal Cancer Therapy in Mesothelioma (selectmeso): a Molecularly Stratified Multi-Arm Phase II Platform Trial for Patients with Relapsed Malignant Mesothelioma

Kayleigh Hill,Dean Fennell, Anna Song,Robin Wickens,Judith Cave,Andrea Corkhill, Jens Hahne,Michelle Lattimore,Peter Wells-Jordan,Nada Nusrat,Sean Dulloo,Charlotte Poile,Gareth Griffiths

Lung Cancer (2024): 107769-107769

引用0浏览0引用

A Gut Microbiota Rheostat to Forecast Response to PDL1-VEGF Blockade in Mesothelioma

Dean Anthony Fennell,Aleksandra Bzura,Amy Branson,Amy King, Jan Rogel,Shaun Barber,Charlotte Poile,James Harber,Zisen Zhou,Catrin Pritchard,Tamihiro Kamata,Peter Wells-Jordan,Nada Nusrat,Essa Baitei,Joanna Dzialo,Anne Thomas,Michael Barer, Kairobi Haldar,Min Zhang

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Bemcentinib and Pembrolizumab in Patients with Relapsed Mesothelioma: MIST3, a Phase IIa Trial with Cellular and Molecular Correlates of Efficacy

Matthew G. Krebs,Amy Branson,Shaun Barber,Charlotte Poile,Amy King,Alastair Greystoke,Sam Moody,Luke Nolan,Molly Scotland,Liz Darlison,Amrita Bajaj,Bruno Morgan,Cassandra Brookes,Peter Wells-Jordan,Catherine Jane Richards,Anne L. Thomas,Dean Anthony Fennell

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用1浏览0引用

Abemaciclib in Patients with P16ink4a-Deficient Mesothelioma (mist2): a Single-Arm, Open-Label, Phase 2 Trial

Lancet oncology/Lancet Oncologyno. 3 (2022): 374-381

引用27浏览0WOS引用

Atezolizumab and Bevacizumab in Patients with Relapsed Mesothelioma: MIST4—a Phase IIa Trial with Cellular and Molecular Correlates of Efficacy

Dean Anthony Fennell,Amy King,Amy Branson,Shaun Barber,Alastair Greystoke,Sean Dulloo,Charlotte Poile,James Harber,Molly Scotland,Liz Darlison,Amrita Bajaj,Bruno Morgan,Cassandra Brookes,Peter Wells-Jordan,Catherine Jane Richards,Anne Thomas

Journal of clinical oncology（2022）

引用0浏览0引用

Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial

The Lancet Respiratory Medicineno. 6 (2021): 593-600

引用0浏览0引用

Rucaparib in Patients with BAP1-deficient or BRCA1-deficient Mesothelioma (mist1): an Open-Label, Single-Arm, Phase 2a Clinical Trial

Dean A. Fennell,Amy King,Seid Mohammed,Amy Branson,Cassandra Brookes,Liz Darlison,Alan G. Dawson,Aarti Gaba,Margaret Hutka,Bruno Morgan,Adrian Nicholson,Cathy Richards,Peter Wells-Jordan,Gavin James Murphy,Anne Thomas

The Lancet Respiratory medicine（2021）

引用56浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn